Mesoblast Financial Statements From 2010 to 2025

MESO Stock  USD 19.52  0.03  0.15%   
Mesoblast financial statements provide useful quarterly and yearly information to potential Mesoblast investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Mesoblast financial statements helps investors assess Mesoblast's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Mesoblast's valuation are summarized below:
Gross Profit
-47.4 M
Market Capitalization
1.1 B
Enterprise Value Revenue
137.1211
Revenue
5.9 M
Earnings Share
(1.05)
We have found one hundred twenty available fundamental ratios for Mesoblast, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Mesoblast's last-minute fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 30th of January 2025, Market Cap is likely to grow to about 1.3 B. Also, Enterprise Value is likely to grow to about 1.2 B

Mesoblast Total Revenue

6.45 Million

Check Mesoblast financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Mesoblast's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.8 M, Interest Expense of 24.9 M or Selling General Administrative of 20.5 M, as well as many indicators such as Price To Sales Ratio of 122, Dividend Yield of 0.0 or PTB Ratio of 1.5. Mesoblast financial statements analysis is a perfect complement when working with Mesoblast Valuation or Volatility modules.
  
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.

Mesoblast Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets583.1 M769.5 M691.2 M
Very volatile
Other Current Liabilities60 M57.1 M18.4 M
Slightly volatile
Total Current Liabilities88.4 M84.2 M53.8 M
Slightly volatile
Total Stockholder Equity419.6 M552.4 M497.7 M
Pretty Stable
Property Plant And Equipment Net3.6 M4.4 M4.5 M
Slightly volatile
Accounts Payable15.1 M8.1 M18.1 M
Very volatile
Cash67.2 M71.9 M63.5 M
Pretty Stable
Non Current Assets Total466.6 M670.1 M567.2 M
Pretty Stable
Cash And Short Term Investments67.2 M71.9 M63.5 M
Pretty Stable
Net Receivables25.3 M24.1 M11.2 M
Slightly volatile
Common Stock Shares Outstanding1.2 B1.1 B378.4 M
Slightly volatile
Liabilities And Stockholders Equity583.1 M769.5 M691.2 M
Very volatile
Other Current Assets3.9 M2.9 M4.8 M
Pretty Stable
Other Stockholder Equity80.3 M84.5 M360.7 M
Pretty Stable
Total Liabilities163.4 M217.1 M193.5 M
Pretty Stable
Property Plant And Equipment Gross29.1 M27.7 M11.4 M
Slightly volatile
Total Current Assets116.5 M99.4 M123.9 M
Slightly volatile
Accumulated Other Comprehensive Income46 M90 M59.6 M
Pretty Stable
Intangible Assets352.8 M507.5 M431.7 M
Pretty Stable
Good Will147.7 M154.6 M136.3 M
Slightly volatile
Non Current Liabilities Total128.2 M104 M154.7 M
Slightly volatile
Short Term Debt25.5 M19 M27.5 M
Very volatile
Common Stock Total Equity939.2 M1.3 B922.4 M
Slightly volatile
Common StockB1.5 B954.5 M
Slightly volatile
Other Liabilities16.3 M17.2 M76.9 M
Slightly volatile
Other AssetsM2.1 M2.5 M
Slightly volatile
Property Plant EquipmentM7.5 M5.5 M
Slightly volatile
Deferred Long Term Liabilities75.7 M44.4 M89.8 M
Slightly volatile
Long Term Investments1.6 M912.6 K1.9 M
Slightly volatile
Net Invested Capital659.7 M683.9 M577.6 M
Slightly volatile
Net Working Capital11.3 M11.9 M29.9 M
Pretty Stable
Short and Long Term Debt Total108.1 M136.8 M84.3 M
Slightly volatile
Long Term Debt81.7 M115.6 M70.8 M
Slightly volatile
Long Term Debt Total69.7 M77.4 M64.1 M
Slightly volatile
Short and Long Term Debt21 M12.5 M39.6 M
Slightly volatile
Capital Stock1.3 B1.5 B1.1 B
Slightly volatile
Capital Lease ObligationsM4.1 MM
Slightly volatile

Mesoblast Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.8 M2.2 M2.3 M
Slightly volatile
Selling General Administrative20.5 M27.2 M24.5 M
Pretty Stable
Total Revenue6.4 M6.8 M17 M
Slightly volatile
Other Operating Expenses73 M103.6 M89.3 M
Slightly volatile
Research Development37.9 M29.2 M44.4 M
Pretty Stable
Total Operating Expenses70.7 M56.3 M83.6 M
Very volatile
Selling And Marketing Expenses25 M18.1 M22.4 M
Very volatile
Cost Of Revenue38.1 M47.2 M33.8 M
Slightly volatile
Non Recurring49.5 M55.7 M60.8 M
Slightly volatile
Reconciled DepreciationM5.4 M3.5 M
Slightly volatile
Interest Income2.2 M2.1 M698.1 K
Slightly volatile

Mesoblast Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation5.8 M6.8 M6.8 M
Pretty Stable
Depreciation5.6 M5.4 M2.9 M
Slightly volatile
Capital Expenditures283 K297.9 K3.4 M
Slightly volatile
End Period Cash Flow104.5 M72.4 M108.1 M
Slightly volatile
Begin Period Cash Flow104.3 M82 M119.1 M
Slightly volatile
Sale Purchase Of Stock45.8 M34.8 M30.5 M
Slightly volatile
Issuance Of Capital Stock58.1 M58.9 M49.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio122128103
Pretty Stable
PTB Ratio1.51.582.4561
Slightly volatile
Days Sales Outstanding1.4 K1.5 K326
Slightly volatile
Book Value Per Share0.530.440.8146
Pretty Stable
Average Payables1.3 M1.2 M1.1 M
Very volatile
Stock Based Compensation To Revenue1.091.140.6655
Slightly volatile
Capex To Depreciation0.07750.08165.4879
Slightly volatile
PB Ratio1.51.582.4561
Slightly volatile
EV To Sales132139102
Pretty Stable
Payables Turnover5.495.232.6552
Slightly volatile
Sales General And Administrative To Revenue4.374.62.6819
Slightly volatile
Research And Ddevelopement To Revenue4.694.944.4648
Pretty Stable
Capex To Revenue0.06130.06450.2472
Slightly volatile
Cash Per Share0.0880.05710.1028
Very volatile
Days Payables Outstanding68.6572.26299
Slightly volatile
Income Quality0.470.52.1552
Pretty Stable
Intangibles To Total Assets0.460.770.7394
Slightly volatile
Current Ratio1.291.362.8945
Slightly volatile
Receivables Turnover0.310.3226.617
Slightly volatile
Graham Number0.920.891.3926
Very volatile
Shareholders Equity Per Share0.530.440.8146
Pretty Stable
Debt To Equity0.150.220.1541
Slightly volatile
Capex Per Share4.0E-44.0E-40.0062
Slightly volatile
Average ReceivablesM5.7 M5.9 M
Slightly volatile
Revenue Per Share0.00650.00690.0302
Slightly volatile
Interest Debt Per Share0.06550.110.0953
Slightly volatile
Debt To Assets0.110.160.1169
Slightly volatile
Price Book Value Ratio1.51.582.4561
Slightly volatile
Days Of Payables Outstanding68.6572.26299
Slightly volatile
Ebt Per Ebit1.31.21.1525
Very volatile
Company Equity Multiplier1.051.251.3392
Slightly volatile
Long Term Debt To Capitalization0.10.160.1141
Slightly volatile
Total Debt To Capitalization0.130.180.1319
Slightly volatile
Debt Equity Ratio0.150.220.1541
Slightly volatile
Quick Ratio1.291.362.0876
Slightly volatile
Net Income Per E B T0.991.150.867
Pretty Stable
Cash Ratio0.930.981.5869
Slightly volatile
Days Of Sales Outstanding1.4 K1.5 K326
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.161.1426
Slightly volatile
Price To Book Ratio1.51.582.4561
Slightly volatile
Fixed Asset Turnover1.681.777.4672
Slightly volatile
Debt Ratio0.110.160.1169
Slightly volatile
Price Sales Ratio122128103
Pretty Stable
Asset Turnover0.00960.01010.0242
Slightly volatile
Price Fair Value1.51.582.4561
Slightly volatile

Mesoblast Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.3 B756.6 M1.1 B
Slightly volatile
Enterprise Value1.2 B821.4 M1.1 B
Slightly volatile

Mesoblast Fundamental Market Drivers

Forward Price Earnings454.5455
Cash And Short Term Investments62.6 M

Mesoblast Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
23rd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of September 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of June 2023
Last Financial Announcement
View

About Mesoblast Financial Statements

Mesoblast investors utilize fundamental indicators, such as revenue or net income, to predict how Mesoblast Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue5.8 M8.8 M
Total Revenue6.8 M6.4 M
Cost Of Revenue47.2 M38.1 M
Stock Based Compensation To Revenue 1.14  1.09 
Sales General And Administrative To Revenue 4.60  4.37 
Research And Ddevelopement To Revenue 4.94  4.69 
Capex To Revenue 0.06  0.06 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(12.83)(13.47)

Pair Trading with Mesoblast

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Mesoblast position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will appreciate offsetting losses from the drop in the long position's value.

Moving against Mesoblast Stock

  0.8PDSB PDS Biotechnology CorpPairCorr
  0.77KRYS Krystal BiotechPairCorr
  0.71JNJ Johnson JohnsonPairCorr
  0.7INZY Inozyme PharmaPairCorr
  0.65MREO Mereo BioPharma GroupPairCorr
The ability to find closely correlated positions to Mesoblast could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Mesoblast when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Mesoblast - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Mesoblast to buy it.
The correlation of Mesoblast is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mesoblast moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mesoblast moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Mesoblast can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Mesoblast offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Mesoblast's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Mesoblast Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Mesoblast Stock:
Check out the analysis of Mesoblast Correlation against competitors.
To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.06
Quarterly Revenue Growth
(0.41)
Return On Assets
(0.05)
Return On Equity
(0.18)
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.